Jamaica’s outlook revised to stable by Fitch after hurricane
Investing.com - BMO Capital has reiterated an Outperform rating on Structure Therapeutics (NASDAQ:GPCR) with a $100.00 price target as the company approaches critical year-end clinical readouts. This target represents significant upside from the current price of $32.84, with analyst targets ranging from $44 to $120. According to InvestingPro data, the stock currently trades near its Fair Value.
The firm highlighted that the upcoming ACCESS I/II Phase 2b trial results for aleniglipron in obesity represent a significant inflection point for the company. These readouts will serve as a benchmark to evaluate whether aleniglipron can compete effectively in the metabolic treatment space. With earnings expected on November 12, investors will be closely watching for updates on these trials.
BMO noted that efficacy expectations have been somewhat tempered following Eli Lilly’s orforglipron results, making the ACCESS data crucial for determining aleniglipron’s market potential.
Structure Therapeutics shares have appreciated nearly 100% over the past three months, reflecting growing investor interest ahead of the readout and recognition of the merger and acquisition potential for mid-phase obesity assets, particularly following recent bids for Metsera.
The company is also expected to initiate a Phase 1 study for ACCG-2671 by year-end, which BMO views as an important step in expanding Structure’s pipeline into the amylin therapeutic area. Despite its promising pipeline, InvestingPro data shows Structure Therapeutics holds more cash than debt and maintains strong liquidity with a current ratio of 14.15, giving it runway to advance its clinical programs.For deeper insights into Structure Therapeutics’ financial health, valuation metrics and more ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Jazz Pharmaceuticals announced the appointment of Ted W. Love, M.D., to its Board of Directors, effective December 1, 2025. This follows the planned retirement of Kenneth O’Keefe from the board on the same date. Dr. Love brings over 30 years of experience in the biopharmaceutical industry, having previously served as President and CEO of Global Blood Therapeutics until its acquisition by Pfizer in 2023. Meanwhile, Structure Therapeutics has caught the attention of several analyst firms. Piper Sandler reiterated an Overweight rating with a $93.00 price target, citing upcoming trial readouts for aleniglipron as potential catalysts. H.C. Wainwright also maintained a Buy rating with a $60.00 price target, emphasizing the drug’s promising early weight loss results and gastrointestinal tolerability. Additionally, Cantor Fitzgerald reiterated an Overweight rating with a $65.00 price target, noting similarities between aleniglipron and other competitive drugs. Lastly, Terns Pharmaceuticals maintained its Market Outperform rating from Citizens, with the firm setting a $20.00 price target, highlighting the company’s unique approach to its oral GLP-1 asset.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.